TK-112690

CAT: 0804-HY-W008491-01Size: 10 gDry Ice: NoHazardous: No
CAT#:0804-HY-W008491-01Size:10 g
Selected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
TK-112690 is a UPP1 inhibitor. TK-112690 inhibits murine small intestinal uridine phosphorylase (UPase) with an IC50 of 12.5 μM and human small intestinal UPase with an IC50 of 20.0 μM in vitro. TK-112690 increases plasma uridine concentration in mice. TK-112690 can be used for the study of cancer and pulmonary fibrosis[1][2][3].
CAS Number
[22423-26-3]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Others
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Concentration
10mM
Purity
99.91
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC(C1=O)=CN(C2=N1)[C@@]3([H])[C@](O2)([H])[C@@](O)([H])[C@@](O3)([H])CO
Molecular Formula
C10H12N2O5
Molecular Weight
240.21
Precautions
H302, H315, H319, H335
References & Citations
[1]Strefeler A, et al. Nucleosides are overlooked fuels in central carbon metabolism. Trends Endocrinol Metab. 2024 Apr;35 (4) :290-299. |[2]William A. Garland, et al. Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same. US 9,382,287 B2. United States Patent and Trademark Office (USPTO) . Jul. 5, 2016. |[3]William A. Garland, et al. Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease. US 2025/0222000 A1. United States Patent and Trademark Office (USPTO) . Jul. 10, 2025.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound2
Clinical Information
No Development Reported

Popular Products